A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol
作者: Inti QurashiImran B. ChaudhryAmeer B. KhosoSana FarooqueSteve LaneMohammad Omair HusainSimon ChuJane SarginsonMunir HamaraniHaider A. NaqviBushra RazzaqueFareed A. MinhasAlison R. YungJ. F. W. DeakinNusrat Husain
作者单位: 1Ashworth Research Centre, Mersey Care NHS Foundation Trust
2Faculty of Medicine, Biology and Health, University of Manchester
3Pakistan Institute of Living & Learning
4Institute of Translational Medicine, University of Liverpool
5Manchester Mental Health and Social Care Trust
6School of Psychology, University of Central Lancashire
7Abbasi Shaheed Hospital
8Ziauddin University
9Institute of Psychiatry & WHO Collaborating Centre
刊名: Trials, 2017, Vol.18 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s13063-017-2275-y
关键词: MinocyclineOmega-3 fatty acidsPUFAAt-risk mental state (ARMS)Ultra-high risk (UHR) schizophreniaGlobal mental health
原始语种摘要: The at-risk mental state (ARMS) describes individuals at high risk of developing schizophrenia or psychosis. The use of antipsychotics in this population is not supported, because most individuals with ARMS are unlikely to develop psychosis. Anti-inflammatory treatments and polyunsaturated fatty acids (PUFAs) may have some beneficial effects in the treatment of ARMS. There have been no controlled clinical trials in which researchers have investigated the use of minocycline for ARMS and no trials involving PUFAs in combination with other proposed treatments. There is a need to find effective, tolerable and inexpensive interventions for individuals with ARMS that are available in high-, low- and middle-income countries.
全文获取路径: Springer Nature  (合作)
影响因子:2.206 (2012)

  • minocycline 二甲胺四环素
  • schizophrenia 精神分裂症
  • psychosis 精神病
  • controlled 受控
  • fatty 脂肪的
  • antipsychotics 抗精神病药
  • omega 奥米加
  • developing 显影
  • treatment 处理
  • usual 通常的